药物涂层球囊治疗慢性肢体威胁性缺血的安全性与疗效:系统综述与荟萃分析
股腘病变12个月一期通畅率82%,膝下病变64%;膝下病变中药物涂层球囊再闭塞风险显著低于普通球囊(10% vs 25%;OR 0.38,95%CI 0.21-0.70,p=0.002),但一期通畅率、靶病变血运重建、大截肢或死亡率无差异。
要点
- 药物涂层球囊治疗慢性肢体威胁性缺血12个月全因死亡率为9%,大截肢率为5%。
- 膝下病变药物涂层球囊再闭塞风险显著低于普通球囊(10% vs 25%;OR 0.38,95%CI 0.21-0.70,p=0.002)。
- 膝下病变药物涂层球囊与普通球囊在12个月一期通畅率、靶病变血运重建、大截肢或死亡率上无差异。
核心结论
- 药物涂层球囊治疗慢性肢体威胁性缺血的股腘和膝下病变可获得可接受的12个月通畅率。
- 膝下病变的对比数据未显示药物涂层球囊具有通畅率优势。
- 药物涂层球囊与普通球囊的12个月死亡率无显著差异,但需更长期研究确定药物涂层球囊使用与死亡率的关系。
研究设计与样本
- 系统检索PubMed、Scopus和Cochrane Central至2020年1月,纳入随机试验和观察性研究。
- 股腘病变1315例,膝下病变793例。
- 采用随机效应模型荟萃分析,报告比值比(OR)和95%置信区间(CI)。
主要发现
- 股腘病变平均长度为121±44 mm,膝下病变平均长度为135±53 mm。
- 总体12个月全因死亡率为9%(95%CI 6%-13%),大截肢率为5%(95%CI 2%-8%)。
- 股腘病变12个月一期通畅率为82%(95%CI 76%-87%),膝下病变为64%(95%CI 58%-70%)。
- 膝下病变敏感性分析显示药物涂层球囊与普通球囊在12个月一期通畅率、靶病变血运重建、大截肢或死亡率方面无差异。
- 膝下病变药物涂层球囊再闭塞风险显著低于普通球囊(10% vs 25%;OR 0.38,95%CI 0.21-0.70,p=0.002)。
临床怎么用
- 药物涂层球囊可用于慢性肢体威胁性缺血股腘和膝下病变的血管内治疗,12个月通畅率可接受。
- 对于膝下病变,药物涂层球囊可能降低再闭塞风险,但未显示一期通畅率、靶病变血运重建、大截肢或死亡率的获益。
- 需关注药物涂层球囊使用与长期死亡率的关系,目前12个月数据未显示显著差异。
局限性
- 对比数据未显示膝下病变药物涂层球囊的通畅率获益。
- 需更长期结局研究以确定药物涂层球囊使用与慢性肢体威胁性缺血患者死亡率的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To investigate the safety and efficacy of drug-coated balloons (DCB) for the treatment of femoropopliteal or infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI). Materials and Methods: A systematic literature search was conducted in PubMed, Scopus, and Cochrane Central up to January 2020 to identify randomized trials and observational studies presenting data on the effectiveness and safety of DCBs in the treatment of femoropopliteal or infrapopliteal lesions. A meta-analysis utilizing random effects modeling was conducted to investigate primary patency and all-cause mortality at 12 months; the results are reported as the odds ratios (ORs) and 95% confidence intervals (CIs). Secondary outcomes were procedural success, bailout stenting, target lesion revascularization (TLR), reocclusion, major amputation, wound healing, and major adverse limb events. Results: Twenty-six studies, 12 retrospective and 14 prospective, comprising 2108 CLTI patients treated with DCBs for femoropopliteal (n=1315) or infrapopliteal (n=793) lesions were analyzed. The average lesion lengths were 121±44 and 135±53 mm, respectively. The overall 12-month all-cause mortality and major amputation rates were 9% (95% CI 6% to 13%) and 5% (95% CI 2% to 8%), respectively. Primary patency rates were 82% (95% CI 76% to 87%) and 64% (95% CI 58% to 70%), respectively. A sensitivity analysis of the infrapopliteal lesions demonstrated no difference between DCB and balloon angioplasty in terms of primary patency, TLR, major amputation, or mortality over 12 months. However, patients with infrapopliteal lesions undergoing DCB angioplasty did have a significantly lower risk for reocclusion (10% vs 25%; OR 0.38, 95% CI 0.21 to 0.70, p=0.002). Conclusion: DCB angioplasty of femoropopliteal and infrapopliteal lesions in patients with CLTI results in acceptable 12-month patency rates, although comparative data have not shown a patency benefit for infrapopliteal lesions. The 12-month mortality rate of DCB vs balloon angioplasty was not significantly different, but studies with longer-term outcomes are necessary to determine any association between DCB use and mortality in patients with CLTI.
引用
- Giannopoulos S, Ghanian S, Parikh SA, et al. Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2020. PMID: 32508220. doi:10.1177/1526602820931559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。